GlassScriptPhysician profile
Martyn D Gordon
NPI 1972689750
$4,538.94
in general payments reported to CMS, 2019-2025
44 companies · $517 in 2025
The $517 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $410 · 2020: $851 · 2021: $973 · 2022: $576 · 2023: $662 · 2024: $551 · 2025: $517.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,730.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,729.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $490.05 | 2019-2024 | Farxiga, Breztri, Airsupra |
| Abbvie INC. | $472.45 | 2020-2025 | |
| Amgen INC. | $438.72 | 2019-2025 | Repatha, Repatha, Otezla |
| Amarin Pharma, INC. | $260.10 | 2020-2023 | |
| Glaxosmithkline, LLC. | $229.75 | 2020-2025 | Shingrix, Trelegy Ellipta, Arexvy |
| Lilly USA, LLC | $229.40 | 2019-2025 | Mounjaro |
| Janssen Pharmaceuticals, INC | $213.42 | 2019-2021 | |
| Abbott Laboratories | $203.85 | 2020-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Medtronic, INC. | $146.27 | 2021-2025 | Inceptiv |
| Pfizer INC. | $143.27 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $137.94 | 2019-2024 | Jardiance |
| Corcept Therapeutics | $136.42 | 2022-2025 | Korlym |
| Merck Sharp & Dohme LLC | $127.74 | 2020-2023 | Belsomra, Steglatro |
| Novo Nordisk INC | $123.49 | 2019-2025 | Ozempic |
| Antares Pharma, INC. | $100.98 | 2020-2022 |
Show all 44 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $95.96 | 2021-2024 | Nexletol |
| Novartis Pharmaceuticals Corporation | $90.80 | 2019-2022 | |
| Bardy Diagnostics, INC. | $87.00 | 2021 | |
| Dexcom, INC. | $67.91 | 2021-2024 | Dexcom G6 Transmitter |
| Eisai INC. | $65.82 | 2020 | |
| Exact Sciences Corporation | $63.99 | 2023-2025 | Cologuard Collection Kit |
| Ibsa Pharma INC. | $61.86 | 2020-2021 | |
| Amneal Pharmaceuticals LLC | $60.30 | 2021-2022 | |
| Idorsia Pharmaceuticals US INC | $54.03 | 2022-2023 | Quviviq |
| Sanofi-Aventis U.S. LLC | $44.65 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $34.80 | 2021-2025 | |
| Astellas Pharma US INC | $32.61 | 2023 | Veozah |
| Tolmar, INC. | $31.73 | 2024-2025 | Jatenzo |
| Azurity Pharmaceuticals, INC. | $27.96 | 2023-2024 | Edarbyclor, Edarbyclor |
| Clarus Therapeutics INC. | $25.88 | 2021 | |
| Intra-Sana Laboratories | $23.58 | 2025 | Reltone 200 Mg, Glycate, Reltone 400 Mg |
| Baxter Healthcare | $20.59 | 2025 | Hillrom - Vest System Model 105 Home Care |
| Althera Pharmaceuticals LLC | $19.50 | 2021-2022 | |
| Aytu Biopharma, INC. | $19.44 | 2020 | |
| Echosens North America, INC. | $19.29 | 2024 | Fibroscan |
| Optos, INC. | $16.86 | 2021 | |
| Kaleo, INC. | $16.35 | 2022 | |
| Medicure Pharma INC. | $16.25 | 2021 | |
| Ethicon US, LLC | $16.24 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $16.09 | 2023 | |
| Jazz Pharmaceuticals INC. | $15.94 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $14.47 | 2023 | Livalo, Seglentis |
| Genentech USA, INC. | $14.02 | 2019 | |
| Allergan, INC. | $11.17 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Martyn Gordon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.